Amerise Biosciences Ltd (AMERISE) Fair Value & Analysis
Financial Services · IN · Market cap ₹5.4M
Fair value as of: Aug 13, 2026
From 6 valuation models · updated 5 days ago
Fair value updated Aug 13, 2026, revised from ₹0.4900 to ₹0.3200 (−34.7%) since Aug 11, 2026.
A solid business, but screening 62% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹0.4000). The favourable scenario is already priced in.
- Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.
- For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹0.5000 – ₹5.60 · fair‑value band ₹0.2400 – ₹0.4000 · the ₹0.8500 price screens above the ₹0.3200 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Amerise Biosciences Ltd (AMERISE) currently trades at ₹0.8500, while our model-based Fair Value estimate is ₹0.3200, implying the stock looks roughly 62.4% overvalued today. The Quality Score stands at 63/100 (solid quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at ₹3.6M. Revenue declined 57.9% year over year. It earns a return on equity of 0.3%. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹0.2400 (bear case) to ₹0.4000 (bull case); at ₹0.8500, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 10% below its 52-week high and 70% above its 52-week low, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -61% fair-value upside, at -62%, AMERISE screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 6 models by family
Widest divergence: Asset-Based (₹5.47) versus Earnings-Based (₹0.1200). Highest evidence: P/E Multiple (63).
Notify me when AMERISE reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 57
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Amerise Biosciences Limited does not have significant operations. Previously, it was involved in the commodity trading business. The company was formerly known as Amradeep Industries Limited and changed its name to Amerise Biosciences Limited in December 2021. Amerise Biosciences Limited was incorporated in 1984 and is based in Ahmedabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Amerise Biosciences Ltd reported revenue of ₹0 in FY2026 versus ₹90.1M in FY2022. Reported net income was ₹161K in FY2026, compounding −58.6%/yr from FY2022.
AMERISE screens 62% overvalued. Compare with The Coca-Cola Company →
Peer Group
Shell Companies · 90 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Shell Companies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Shell Companies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Coca-Cola Company COLA | C$30.34 | C$10.62 | -65% |
| Lionheart III Corp LION | $11.73 | $18.15 | +55% |
| Agriculture & Natural Solutions Acquisition Corporation ANSC | $11.46 | $4.13 | -64% |
| AA Mission Acquisition Corp AAM | $0.0390 | $0.0394 | +1% |
| GP-Act III Acquisition Corp GPAT | $11.16 | $4.30 | -61% |
| Metals Acquisition Corp MTAL | $10.24 | $20.48 | +100% |
| Berto Acquisition Corp TACO | $10.45 | $2.73 | -74% |
| Axiom Intelligence Acquisition Corp AXIN | $10.29 | $1.46 | -86% |
| Bold Eagle Acquisition Corp BEAG | $10.75 | $4.00 | -63% |
| Lionheart Holdings CUB | $10.88 | $5.06 | -53% |
Compare Amerise Biosciences Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Amerise Biosciences Ltd (AMERISE) overvalued or undervalued?
What is the fair value of AMERISE?
What is the quality score of AMERISE?
What is the revenue of Amerise Biosciences Ltd (AMERISE)?
What is the net profit margin of AMERISE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Amerise Biosciences Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.